SER-301

SER-301 is a consortium of cultivated bacteria SER-401 (developed by Seres Therapeutics Inc.) designed using reverse translational discovery platform. This platform incorporates:

• Analysis of microbiome biomarkers from human clinical data


• Preclinical assessments using human cell-based assays


• In vitro/ex vivo and in vivo disease models

SER-301 is designed to:

• Reduce induction of pro-inflammatory activity


• Improve epithelial barrier integrity


• Mitigate TNF-alpha driven inflammation in intestinal epithelial cells (IECs)


• Modulate UC-relevant anti-inflammatory, innate, and adaptive immune pathways

SER-301 is produced using advanced fermentation, formulation, and delivery platforms. It includes:

• Strains delivered in spore form


• Strains cultiv…